Related by context. All words. (Click for frequent words.) 83 PANSS Positive 63 Rating Scale MADRS 62 Scale PANSS 62 Negative Syndrome 61 Montgomery Asberg Depression 60 Montgomery Åsberg Depression 60 PANSS 59 UACR 59 Pharmacokinetic parameters 58 Brief Psychiatric 58 Negative Symptoms 58 somatostatin analog 58 Beck Anxiety Inventory 58 Numeric Rating Scale 58 Pain Intensity 57 Treatment Outcome 57 hematological parameters 57 Negative Symptom Scale PANSS 57 Alzheimer Disease Assessment 57 Psoriasis Area 57 Demonstrated Significant 57 ACR# ACR# 57 Index CDAI 56 MSLT 56 STAI 56 Hamilton Anxiety Scale 56 HOMA IR 56 ADCS CGIC 56 Predictive Value 56 Prognostic Value 56 Pharmacodynamics 56 Pharmacodynamic 56 HDRS 56 International Prostate Symptom 56 8mg/kg 56 EMRG VIO 56 trough FEV1 55 Visual Analog Scale 55 Severity Index PASI 55 Primary endpoints 55 Double Blind Randomized 55 Main Outcome Measure 55 CNS LS 55 POL PRO 55 By JENNIFER LEARN 55 certolizumab 55 aspartate aminotransferase 55 mU liter 55 UPDRS 55 YMRS 55 tipranavir r 55 Placebo Controlled Trial 55 Brief Pain 55 Score TOS 55 Score IPSS 54 nasal symptom 54 State Examination MMSE 54 SSRI citalopram 54 TNSS 54 DAS# CRP 54 MADRS 54 Main Outcome Measures 54 Coronary Artery Calcium 54 Global Impression CGI 54 elevated transaminases 54 Pearson correlation coefficient 54 ug kg 54 scores TNSS 54 creatinine ratio 54 ADHD Rating Scale 54 Unified Parkinson Disease 54 Functional Assessment 54 Symptom Severity 54 lactate dehydrogenase LDH 54 subscale scores 54 NOAEL 54 Oral Fingolimod 54 urinary N telopeptide 53 RU EUROPE EEU EMRG 53 Treatment Diabetic Retinopathy 53 Randomized Evaluation 53 undetectable HBV DNA 53 Hospitalized Patients 53 Cystatin C 53 Inventory BPI 53 Scale Cognitive Subscale 53 fosbretabulin 53 Mean Symptom Complex 53 serum phosphorous 53 Severity Index 53 -#.# mg dL [002] 53 Fibromyalgia Impact Questionnaire 53 DAS# remission 53 calculated creatinine clearance 53 Significantly Improved 53 HADS 53 Crohn Disease Activity 53 CHAMPION PCI 53 ADAS Cog 53 Wilcoxon rank sum 53 Novel Inhibitor 53 achieved ACR# 53 Left Ventricular 53 lumbar spine BMD 53 DAS# scores 53 Secondary endpoints included 53 MADRS score 53 fasting plasma glucose FPG 53 albumin excretion rate 53 PANSS total 53 -#.# ± [002] 52 -#.# log# copies mL 52 Clinician Administered PTSD 52 APACHE II 52 Prolongs Survival 52 Non inferiority 52 IPSS 52 Expanded Disability Status 52 MAXIMA 52 Non Responders 52 thyroglobulin 52 cells mcL 52 fasting plasma 52 ADAS cog 52 cEVR 52 Novel Compound 52 SPIRIT FIRST 52 TIMP 1 52 ^ Tc 52 Rating Scale UPDRS 52 log# copies mL 52 Clinical Outcome 52 aspartate aminotransferase AST 52 AST ALT 52 ICAEL 52 subjective sleepiness 52 Abnormal Involuntary Movement 52 oxycodone CR 52 Cardiorespiratory fitness 52 Neuropsychiatric Inventory NPI 52 rFSH 52 ISOCOUNTRY3 52 HBeAg + 52 IRLS 52 Orally Active 52 Chronic Illness Therapy 52 Scale EDSS 52 Ejection Fraction 52 VFQ 52 RU EEU EUROPE ASIA 52 BENICAR 52 RECIST Response Evaluation Criteria 52 Global Impression 52 Controlled Trial 52 ADCS ADL 52 CFQ R 52 glycosylated hemoglobin HbA1c 52 serum cortisol 52 Susceptibility Testing 52 Symptom severity 52 Rating Scale 52 Index FSFI 52 μg kg 52 -#.# log# 52 serum prostate 52 Visual Analogue Scale VAS 52 Cardiotoxicity 51 specific antigen PSA 51 apnea hypopnea index 51 fructosamine 51 Hamilton Rating Scale 51 Solid Tumours 51 Visual Analog 51 Dyspnea 51 PCWP 51 CDAI 51 ACE Inhibitor 51 4mg/kg 51 OGTT 51 Somnolence 51 MCID 51 alanine aminotransferase ALT 51 Prostate specific antigen 51 EBMT criteria 51 urine albumin 51 Echocardiographic 51 Score DAS 51 PEGylated anti 51 GAMMAGARD 51 HAM D 51 Liraglutide Effect 51 hemagglutination inhibition 51 PDSS 51 HBeAg seroconversion 51 ritonavir boosted 51 Oral Glucose Tolerance 51 HAMD 51 FFNS 51 neuropathy sensory 51 LH FSH 51 BPRS 51 Contrast Enhancement 51 Systemic Sclerosis 51 Late Breaker 51 NSABP B 51 Clinical Evaluation 51 Polymorphism 51 transcranial Doppler ultrasound 51 Ranolazine 51 PTI COR 51 Capacity FVC 51 Fecal Incontinence 51 Arch Facial Plast 51 CGIC 51 IIEF 51 Dose Response 51 ANCOVA 51 Orthostatic Hypotension 51 REVIVE Diabetes 51 Sustained virologic response 51 fludarabine cyclophosphamide 51 Hematocrit 51 ACTEMRA TM 51 glucose insulin 51 doxorubicin cyclophosphamide 51 echocardiographic parameters 51 DAS# [002] 51 ng dl 51 RU EUROPE ASIA EEU 51 glomerular filtration rate 51 relapsed MM 51 Severity MSCS score 51 NIH CPSI 51 EURIDIS 51 Rating Scale BPRS 51 Antitumor 51 Endocrine Therapy 51 WAIS III 51 hemoglobin A1c HbA1c 51 Outcome Measures 50 Atomoxetine 50 SF #v# 50 Levels Linked 50 Study Shows Benefits 50 Diabetic Foot Ulcer 50 Inflammatory Markers 50 plasma renin activity 50 Tumor Response 50 #mg/day [001] 50 Response Evaluation Criteria 50 -#.# mg dL [001] 50 Natural Catastrophe Stress 50 ULORIC 50 Cockcroft Gault 50 serum urate 50 Hemodialysis Patients 50 EP4 50 Test Methodology 50 glycated hemoglobin 50 Quantitation 50 6MWD 50 retest reliability 50 Laryngeal Cancer 50 bivalirudin monotherapy 50 Lower Limb 50 intraclass correlation coefficient 50 mL/min/#.# m 2 50 IBDQ 50 Platelet Aggregation 50 hemoglobin Hb 50 Univariate 50 Immunomodulatory 50 Acute Physiology 50 alanine aminotransferase 50 Maturity Model Integration CMMI 50 serum bilirubin 50 glycated hemoglobin HbA1c 50 Maturity Level 5 50 Titration 50 Secretory 50 ACR# response 50 eNO 50 Thrombolysis 50 sUA 50 pharmacodynamic PD 50 Inc. LCV RA 50 Cystic Fibrosis Questionnaire Revised 50 Abdominal Fat 50 IL#B 50 Albuminuria 50 Pharmacokinetic 50 Solid Tumors 50 SVR# 50 Secondary efficacy endpoints 50 RAPAFLO R 50 Cholinesterase Inhibitors 50 EDEMA3 trial 50 Arterial Hypertension 50 bronchial hyperresponsiveness 50 UPDRS Part III 50 Cinacalcet HCl 50 ANOVA 50 Homeostasis 50 inhibin B 50 subscore 50 = #.#-#.# 50 #mg QD [002] 50 mg BID dose 50 mITT population 50 CIMZIA TM 50 EF Domain 50 Calorimetry 50 affective psychosis 50 Estrogen Receptor 50 serum leptin 50 Mutational 50 Repeatability 50 Common Terminology Criteria 50 Microalbuminuria 50 Risk Stratification 50 CrCl 50 Non Alcoholic Steatohepatitis 50 serum CRP 50 apolipoprotein B 49 Myocardial Perfusion 49 Shows Promise Against 49 Bioavailability 49 glycosylated hemoglobin 49 pain subscale 49 liver histology 49 secondary efficacy endpoint 49 semiquantitative 49 Prospective Randomized 49 Showed Significant 49 creatinine clearance 49 Neuropsychiatric Inventory 49 FACIT Fatigue 49 Autologous Stem Cell Transplantation 49 Histologic 49 ARB telmisartan 49 transaminase 49 Disease Severity 49 mg qd 49 Respiratory Symptoms 49 IFN α 49 Scale EDSS score 49 GRN N 49 Depression Inventory BDI 49 Improves Outcomes 49 Lubiprostone 49 Endothelial Function 49 FDG-PET/CT 49 Depressive Symptoms 49 CD# CD# 49 clinically meaningful improvement 49 adiponectin concentrations 49 Scale CNS 49 Pain Rating Scale 49 Hepatitis C Treatment 49 immunoreactivity 49 μmol L 49 RLY 49 Acute Decompensated Heart Failure 49 Therapy Improves 49 glomerular filtration 49 Health Assessment Questionnaire 49 UPDRS motor 49 mineral density BMD 49 PEG IFN 49 J Foot Ankle 49 aPTT 49 Low Emitting 49 Demonstrates Sustained 49 LOCF 49 Disease Activity 49 Interrater reliability 49 Dose Ranging 49 immunostaining 49 Sentinel Lymph Node 49 WOMAC 49 MoxDuo TM IR 49 Epithelial Cell 49 Renal Insufficiency 49 univariate 49 C Reactive Protein 49 Thrombotic 49 #/#mg 49 Adjuvant Therapy 49 Ischemic Stroke 49 achieved statistical significance 49 Loss Severity 49 Dehydrogenase 49 WOMAC TM 49 GFAP 49 Oropharyngeal 49 Hepatotoxicity 49 CK # plasma 49 Hematological Cancers 49 EMRG POL 49 MDQ 49 Prove Effective 49 oral allopurinol 49 MIC# [001] 49 BARACLUDE r 49 antibody titer 49 Carotid Endarterectomy 49 Lipid Levels 49 endoscopic remission 49 Erectile Function 49 Lupus Drug 49 Angiogenic 49 EQ 5D 49 IKDC 49 dimeglumine 49 intraclass correlation coefficients 49 % Confidence Interval 48 Predict Dementia 48 Cmax 48 Mania Rating Scale 48 TGZ 48 Clinical Efficacy 48 μg mL 48 CSBM 48 Forced Vital 48 Repeatable Battery 48 Logistic regression 48 Treating Chronic 48 Cardiovascular Disease Risk 48 PARP Inhibitor 48 Subgroup Analysis 48 Histological 48 Outcomes Study 48 hepatic enzyme 48 clinically meaningful reductions 48 HAQ DI 48 interrater reliability 48 Conjugate 48 Viral load 48 Helps Predict 48 Cognitive Function 48 imipramine Tofranil 48 Histopathological 48 Shows Promising 48 Platelet Function 48 Functional Capacity 48 Practice Guideline 48 Prognostic 48 Protease Inhibitors 48 Pearson correlation coefficients 48 Beta Amyloid 48 Status Scale EDSS 48 urinary albumin 48 salmeterol fluticasone propionate 48 preoperative PSA 48 RRM1 48 Personality Questionnaire 48 F FDG PET 48 Quotient TM 48 Prostatic 48 PTI MIJ 48 Cardiac Function 48 3rd edn 48 erection hardness 48 Depression Scale 48 Integrase Inhibitor 48 overnight polysomnography 48 Functioning GAF 48 Genotypic 48 Attenuates 48 Functional Outcomes 48 Subtype 48 Maturity Level 3 48 Partial Response 48 lymphocyte count 48 CC genotype 48 Stent Restenosis 48 Cariprazine 48 CDAI score 48 Depression Inventory 48 Epworth Sleepiness Scale 48 Fracture Risk 48 Tiotropium 48 SSRI SNRI 48 NVLAP 48 MCyR 48 Reperfusion 48 CIMZIA TM certolizumab pegol 48 Cognitive Abilities 48 Lipid Lowering 48 XPEL Announces 48 Assessment Scale 48 Uric Acid 48 ug dose 48 chi squared 48 Inflammatory Pain 48 Novel Approach 48 ST Segment Elevation 48 Antidepressant Treatment 48 microvessel density 48 Low Incidence 48 QIDS SR 48 PIA SarGen top 48 Ag Cu 48 RT qPCR 48 urothelial 48 Neurosurgical Products 48 Anxiety Depression 48 Combo Therapy 48 Skin sterol 48 Descriptive statistics 48 MAKE WHOLE CALL 48 prasterone 48 Angiographic 48 TMC# C# 48 Therapy Reduces 48 multicentre randomized 48 CR CRu 48 activated partial thromboplastin 48 prospectively stratified 48 moderate renal impairment 48 PRAI 48 Test Detects 48 Distress Scale 48 mg/m2/day 48 multivariate Cox 48 FDG PET imaging 48 Darbepoetin alfa 48 International Prognostic Scoring 47 erythrocyte sedimentation rate 47 fasting plasma glucose 47 Endothelial dysfunction 47 Skin Irritation 47 baseline FEV 47 x ULN 47 MMSE 47 ACR# responses 47 Biological Effects 47 Prospective Multicenter 47 Alzheimer Disease Cooperative 47 NIHSS 47 Comparators 47 Macrophage 47 MIVI TRUST 47 Ischaemic 47 Wechsler Adult 47 HER2 expression 47 Treatment Reduces 47 THEO TORONTO 47 HI titers 47 Secondary endpoints 47 Index HAQ DI 47 creatine kinase 47 azacytidine 47 RENAL 47 Kaplan Meier estimates 47 Intertek Acquires 47 Ultrasound Guided 47 Sensitivity specificity 47 SEI Software 47 PTI SJY 47 Depression Rating Scale 47 lopinavir r arm 47 Geriatric Depression 47 Protein Synthesis 47 Cardiac Resynchronization 47 Watchful Waiting 47 XIENCE V PROMUS Stent 47 NYHA functional class 47 QTcF 47 Sleep Disturbances 47 iPTH 47 macroalbuminuria 47 Pharmacogenetic 47 CsA 47 Revises Rating Outlook 47 Medication Adherence 47 nausea photophobia 47 Natalizumab 47 fasting serum 47 Subscale 47 CRp 47 pT2 47 Often Misdiagnosed 47 aldosterone antagonist 47 Vertebral Fractures 47 Rate ORR 47 microalbumin 47 serum lipid levels 47 ETDRS 47 QT Prolongation 47 JMR Sunnex 47 RE LY trial 47 Clinical Practice Guideline 47 Standardized Assessment 47 Proliferative 47 Cardiopulmonary bypass 47 efficacy endpoint 47 Transdermal Delivery 47 baseline Hb 47 baseline PASI 47 irbesartan 47 posttest 47 Hemoglobin A1c 47 Heart Rate Variability 47 Assigns LS 47 Antiviral Activity 47 Neoadjuvant Chemotherapy 47 Polymorphisms 47 pharmacodynamic parameters 47 Prognostic Index 47 IRLS score 47 baseline serum creatinine 47 Cronbach alpha 47 walk distance 6MWD 47 thyroid peroxidase 47 Kidney Function 47 CCyR 47 RAEB 47 COZAAR 47 bortezomib refractory 47 Major Averages Remain Firmly 47 NGSP 47 DLTs 47 HAM D# 47 Improve Patient 47 mcg kg 47 Clinical Significance 47 Adverse Event 47 ClearWay TM 47 Significant Improvements 47 OZG 47 Statistically Significant 47 telaprevir dosed 47 Radiographic 47 rs# [004] 47 oral glucose tolerance 47 Viral Suppression 47 Profile SEP 47 immunohistochemical analysis 47 -#.# ± [001] 47 LEAP iLEAP 47 catechol O methyltransferase 47 Pregnancy Outcomes 47 Results Confirm 47 macrophage inflammatory protein 47 APTIVUS 47 SCr 47 leukocyte count 47 Coronary Calcium 47 Recombinant EPO 47 Visual acuity 47 subscales 47 glycosylated hemoglobin levels 47 Localized Prostate Cancer 47 BMI z 47 variant rs# 47 IELT 47 premorbid 47 Rosenberg Self Esteem 47 Index CDAI score 47 ERalpha 47 Brain Metastases 47 Erectile Function IIEF 47 clinicopathological features 47 subscores 47 Phosphorylation 47 Severity Scale 47 Renal Function 47 prospectively defined 47 angiotensin converting enzyme 47 epoetin beta 47 PSE Graded Certificate 47 Viral Load 47 Elastography 47 hypogonadal 46 Breast Cancer Recurrence 46 cognitive affective 46 Helps Relieve 46 PATRICK CORRIGAN TORONTO 46 chlorambucil 46 #mg/m# [002] 46 Meta Analysis 46 hsCRP 46 Lowers Blood Pressure 46 dyspnoea 46 HBsAg 46 MMSE score 46 logistic regression analysis 46 serum concentrations 46 albumin creatinine ratio 46 Liver Function 46 aminotransferase 46 ALT elevations 46 Lp PLA 2 46 salivary cortisol 46 placebo p = 46 DK DK 46 transthoracic echocardiography 46 viral kinetics 46 Exposure Linked 46 Cognitive Abilities Test 46 posttreatment 46 exhaled nitric oxide 46 Electrical Stimulation 46 GBX1 #.# [001] 46 AFNOR 46 Incontinence Impact Questionnaire 46 biopsy Gleason 46 Cognitive Problems 46 Stenting Trial 46 statistical significance p 46 Amplicor 46 ASIA Impairment 46 plasma lipids 46 Oral Fluid 46 Academic Proficiency 46 SELENA SLEDAI 46 secondary endpoint 46 FDG PET scans 46 metabolite concentrations 46 Randomized Study 46 NEAP 46 thyrotropin 46 Secondary endpoints include 46 Prostate Cancer Recurrence 46 estimated GFR 46 total cholesterol triglycerides 46 NIS LL 46 Hb A1C 46 maximal dose 46 Progenitor Cells 46 piperacillin tazobactam 46 HA RA 46 Physiologic 46 dehydroepiandrosterone sulfate 46 Molecular Mechanism 46 Lowers Risk 46 CLARITY study 46 BALF 46 spontaneous bowel movements 46 multivariable analysis 46 Chronic Obstructive Lung 46 Substantially Reduce 46 Improves Quality 46 fluoxetine paroxetine 46 Breast Carcinoma 46 Infarct 46 Hypertrophy 46 Scale cognitive subscale 46 SEI Capability Maturity Model 46 CALGB 46 Ankylosing Spondylitis 46 Reduces Mortality 46 Magnetic Stimulation 46 Lifeguard Safeguard 46 CZP 46 Improving Efficiency 46 Common Toxicity Criteria 46 HT 1A 46 elevated creatinine 46 BY CYNTHIA H. 46 histologically confirmed 46 DLQI 46 Postdoctoral Position 46 Histone H3 46 univariate analysis 46 TIPI 46 AOQ MT 46 Glasgow Coma Scale 46 demonstrated clinically meaningful 46 anti JCV antibodies 46 logistic regression 46 CLL SLL 46 confidence intervals CIs 46 Myocardial 46 hemodynamic variables 46 urinary cortisol 46 Stent Placement 46 Rating Scale IRLS 46 Diagnostic Criteria 46 BiTE Antibody 46 PegIFN RBV 46 antithymocyte globulin 46 log# IU mL 46 Univariate analysis 46 Visual Analogue Scale 46 Systolic Blood Pressure 46 non menstrual pelvic 46 Ocular Surface Disease 46 Y BOCS 46 OQ 46 Reveals Significant 46 Virologic Response 46 vasomotor 46 Abdominal Pain 46 ACR# [002] 46 STRATEGY FOR AN OPEN 46 depressive symptom 46 Current Controlled Trials 46 Strongly Linked 46 haematologic 46 Symptom Checklist 46 Percentile 46 Comorbidities 46 orthostatic 46 Adalimumab 46 Severe Asthma 46 ADHD RS 46 serum urate levels 46 HBV DNA levels 46 Disorders Identification 46 carboxylase 46 Edinburgh Postnatal Depression 46 alfuzosin 46 State Trait Anxiety 46 Psychological Distress 46 LV ejection fraction 46 Hematological 46 GERD symptom 46 Platelet counts 46 plus medroxyprogesterone acetate 46 Hypertriglyceridemia 46 NTx 46 Highly Selective 46 pCR 46 ELISPOT 46 Differential Diagnosis 46 LDH lactate dehydrogenase 46 AHEI 46 Aloxi injection 46 CTEPH 46 CR nPR 46 CYP #D# 46 By DON McDERMOTT 46 TIMP 46 AUC0 46 VKORC1 46 Tumor Marker 46 sensitivity specificity 46 Intervention Trial 46 PROTECTED AREAS 46 mRS 46 nerve conduction velocity 46 Cervical Cancer Detection 46 Study Casts Doubt 46 relapsing multiple sclerosis 46 laboratory abnormalities 46 Drug Shows Promise 46 Myocardial Ischemia 46 Predict Risk 46 Major Adverse Cardiac 46 Physical Function 46 Physical Component 46 intima media thickness IMT 46 number NCT# ClinicalTrials.gov 46 plasma cortisol 46 Electroencephalography 46 lowest tertile 46 Nucleic Acid Amplification 46 Cognitive Ability 46 maternal serum 46 pT3 46 PSA nadir 46 Multiple Myeloma Patients 46 Immunohistochemistry 46 6MWT 46 Elitek 46 Inflammatory Arthritis 46 Continual Improvement 46 Ashworth Scale 46 idiopathic membranous nephropathy 46 analgesic efficacy 46 Phenotypic 46 State Exam MMSE 46 pretreatment baseline 46 anthropometric measurements 46 HbA1C 46 Transthyretin 46 Acute Coronary Syndromes 46 FOLFOX regimen 46 TURBT 46 FDA Approves Drug 46 Molecular Weight 46 serum PSA 46 symptom severity 46 clinically meaningful improvements 46 Reduces Pain 46 fasting insulin 45 Quantifiable 45 Digit Symbol Substitution 45 COPERNICUS 45 Confirmatory 45 angiotensin II receptor blockers 45 icatibant 45 sub maximal 45 Restless Legs 45 Synthase 45 euthymic patients 45 Pharmaceuticals Initiates 45 Graduation Required Assessments 45 Glycemic Control 45 ZACTIMA 45 HbA 1c 45 Treat Anemia 45 multiple logistic regression 45 Effective Treatments 45 Key secondary endpoints 45 Stress Induced 45 Metallic Materials 45 morphometric vertebral fractures 45 MAXALT 45 Genetic Marker 45 Further Validates 45 Expedited Review 45 highest tertile 45 achieved CCyR 45 Kaplan Meier method 45 serologically active patients 45 lymphovascular invasion 45 correlation coefficients 45 Nutritional Status 45 Myocardial Infarction 45 r2 = 45 Breast Tissue 45 serum triglyceride levels 45 Capesaris 45 Maven Semantic 45 LDL HDL 45 Multicenter Phase 45 Veröffentlichung einer 45 Permeability 45 ABCB1 45 serum HBV DNA 45 WOMAC pain 45 thyroid stimulating hormone 45 AERIUS 45 Radiation Therapy Oncology 45 APTIMA HPV 45 Septic Shock 45 multivariate regression analysis 45 corticosteroid dose 45 Oral Compound 45 genotypic resistance 45 schizophrenia schizoaffective disorder 45 Logistic Regression 45 Adenomas 45 Systematic Approach 45 Gastrointestinal Tract 45 Functioning Scale 45 Symptom Score 45 bone scintigraphy 45 Nephrogenic 45 unpaired t 45 Timed Walk 45 WOMAC scores 45 pmol L 45 Soft Tissue Sarcoma 45 immunohistochemical 45 Aptivus ® 45 Iron Overload 45 HCV replicon 45 Proficiency Testing 45 doxorubicin docetaxel 45 -#.# mmol L 45 Circadian Clock 45 Capability Maturity Model CMM 45 Carotid Artery Stenting 45 thickness CIMT 45 CAPRA 45 Haptoglobin 45 creatinine 45 corrected QT interval 45 Fkft 45 SGRQ 45 methylenetetrahydrofolate reductase 45 Virus Linked 45 ATTAIN 45 Heat Dissipation 45 serum HCV RNA 45 CI -#.# 45 Atopic Dermatitis 45 Hospital Acquired Pneumonia 45 #.#/#.# mmHg [001] 45 Macroscopic 45 Photometric 45 definite stent thrombosis 45 Dementia Diagnosis 45 Brain Function 45 annualized relapse 45 mL/min/#.# m2 45 Benign Prostatic Hyperplasia 45 symptomatic VTE 45 prospective multicentre 45 nonsignificant 45 Immune Cell 45 estimated glomerular filtration 45 Intraocular Pressure 45 Sustained Virologic Response 45 subtest